Prognoza
| Kupuj |
1 |
| Trzymaj |
1 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Kazia Therapeutics announces capital raise of about $40m, shares fall
Kazia Therapeutics said it will sell 2,580,000 ADS at $15.50 each, expecting gross proceeds of around $40m before fees. In addition, series A and series B warrants are being offered, the exercise of which could generate a further roughly $80m; exercise conditions are tied to the release of clinical trial data for certain breast cancer subtypes. The funds are intended primarily to finance the clinical development of lead candidate Paxalisib and to provide working capital. The offering, accompanied by Leerink Partners, Guggenheim, BTIG and Needham, is expected to close around August 31, 2026; the ADRs fell about 6.2% in premarket trading. » Więcej na de.investing.com
Kazia: Paxalisib shows high response rate in metastatic triple-negative breast cancer
In an ongoing phase 1b study of Paxalisib in combination with pembrolizumab and chemotherapy, six evaluable patients with metastatic triple-negative breast cancer derived clinical benefit. Five of the six patients achieved an objective response (1 complete, 4 partial remissions; objective response rate 83%), and the remaining patient had disease stabilization; responses occurred about three months after randomization and involved, among others, lung, liver, bone, lymph node and CNS lesions. Marked median reductions in circulating tumor cell clusters (83%) and terminally exhausted T cells (51%) were observed, without serious adverse events attributed to Paxalisib. Recruitment is expected to continue until July 2027, with interim results announced for 2026 and 2027. » Więcej na de.investing.com
Kazia Therapeutics reports promising preclinical data on protein degrader NDL2
Kazia Therapeutics released preclinical data on NDL2, a potential first-in-class protein degrader designed to eliminate nuclear PD-L1. In triple-negative breast cancer models, NDL2 reduced tumor volume as monotherapy by 49% and in combination with anti-PD-1 by 73%, and reduced lung metastases by 50%. The program showed no observed toxicity; IND-enabling studies are ongoing and first clinical trials are planned for 2027, with additional data expected in 2026. » Więcej na de.investing.com
Kazia Therapeutics meets Nasdaq listing requirements again, hearing canceled
Kazia Therapeutics reports that it has again met Nasdaq listing requirements, resulting in the cancellation of the hearing scheduled for January 8, 2026. The company has now satisfied the alternative minimum requirement of $2.5 million in stockholders’ equity under Listing Rule 5550(b)(1). Its American Depositary Shares remain listed on the Nasdaq Capital Market. » Więcej na de.investing.com
Kazia Therapeutics secures 46.5 Mio. USD through private placement and meets Nasdaq requirement
Kazia Therapeutics raised net proceeds of approximately 46.5 million USD through a private placement. The company sold 4,530,854,000 common shares at 0.01 USD each and issued pre-funded warrants for up to 938,490 ADS at 4.9999 USD each; each ADS represents 500 common shares. Konik Capital Partners acted as placement agent and also received warrants to purchase up to 700,013 ADS at 7.50 USD, exercisable after 180 days with a five-year term. Kazia expects the transaction to result in equity above the 2.5 million USD minimum required for continued listing on the Nasdaq Capital Market and will notify the Nasdaq Hearings Panel of the restoration of compliance. » Więcej na de.investing.com
Dane finansowe
W ostatnim roku Kazia Therapeutics osiągnęła przychody w wysokości 1,43 mln € i zysk netto w wysokości -16,65 mln €
| (EUR) | 2024 | YoY |
|---|---|---|
| Przychody | 1,43 mln | 423 466,03% |
| Zysk brutto | 1,43 mln | 423 466,03% |
| Zysk netto | -16,65 mln | 33,27% |
| EBITDA | -16,64 mln | 22,38% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 11,49 mln € |
Liczba akcji | 236,35 mln |
Maksimum/minimum z 52 tygodni | 0,15 € - 0,031 € |
| Dywidendy | Nie |
Beta | 2,13 |
C/Z (PE Ratio) | -0,01 |
PEG (PEG Ratio) | 0,00 |
C/WK (PB Ratio) | 0,01 |
C/S (PS Ratio) | 128,14 |
Profil spółki
Kazia Therapeutics Limited, firma biotechnologiczna skupiona na onkologii, opracowuje leki przeciwnowotworowe. Jej wiodącym kandydatem na lek w fazie rozwoju jest Paxalisib, drobnocząsteczkowy inhibitor szlaku PI3K/Akt/mTor, przenikający przez barierę krew-mózg, który jest rozwijany jako potencjalna terapia glejaka wielopostaciowego. Firma rozwija również EVT801, lek badawczy przeznaczony do różnych postaci raka. Spółka wcześniej działała pod nazwą Novogen Limited i zmieniła nazwę na Kazia Therapeutics Limited w listopadzie 2017 roku. Kazia Therapeutics Limited została założona w 1994 roku i ma siedzibę w Sydney w Australii.
| Nazwa | Kazia Therapeutics |
| CEO | John E. Friend II, |
| Siedziba | Sydney,
nsw Australia |
| Strona internetowa | |
| Debiut giełdowy | 30.09.1994 |
| Pracownicy | 12 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
Australian Securities Exchange Ltd | KZA.AX |
Frankfurt | NV9.F |